These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 4762933)

  • 21. In vitro cytotoxicity by a nonthymus-processed lymphocyte population with specificity for a virally determined tumor cell surface antigen.
    Lamon EW; Skurzak HM; Klein E; Wigzell H
    J Exp Med; 1972 Nov; 136(5):1072-9. PubMed ID: 4117188
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus.
    Kirchner H; Chused TM; Herberman RB; Holden HT; Lavrin DH
    J Exp Med; 1974 Jun; 139(6):1473-87. PubMed ID: 4598016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Further evidence for the involvement of thymus-processed lymphocytes in syngeneic tumor cell cytolysis.
    Plata F; Gomard E; Leclerc JC; Levy JP
    J Immunol; 1973 Sep; 111(3):667-71. PubMed ID: 4542607
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor induction by murine sarcoma virus in AKR and C58 mice. Reduction of tumor regression associated with appearance of Gross leukemia virus pseudotypes.
    Chieco-Bianchi L; Colombatti A; Collavo D; Sendo F; Aoki T; Fischinger PJ
    J Exp Med; 1974 Nov; 140(5):1162-79. PubMed ID: 4608945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulatory effect of immunization on tumor induction by Moloney murine sarcoma virus.
    Murasko DM; Prehn RT
    J Natl Cancer Inst; 1978 Nov; 61(5):1323-7. PubMed ID: 213613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus.
    Collins JJ; Roloson G; Haagensen DE; Fischinger PJ; Wells SA; Holder W; Bolognesi DP
    J Natl Cancer Inst; 1978 Jan; 60(1):141-52. PubMed ID: 203701
    [No Abstract]   [Full Text] [Related]  

  • 27. Nature and complexity of the FMR antigenic system.
    Bismuth A; Kremsdorf D; Debré P; Levy JP
    Eur J Immunol; 1979 Aug; 9(8):632-9. PubMed ID: 556553
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumor specific antigens in viral neoplasms and in unrelated virus infected tumors.
    Sjögren HO
    Ann Med Exp Biol Fenn; 1966; 44(2):227-31. PubMed ID: 4290659
    [No Abstract]   [Full Text] [Related]  

  • 29. Blocking of syngeneic effector T cells by soluble tumour antigens.
    Plata F; Levy JP
    Nature; 1974 May; 249(454):271-4. PubMed ID: 4545403
    [No Abstract]   [Full Text] [Related]  

  • 30. Murine leukemia and sarcoma viruses: further studies on the antigens of the viral envelope.
    Gomard E; Leclerc JC; Levy JP
    J Natl Cancer Inst; 1973 Apr; 50(4):955-61. PubMed ID: 4122212
    [No Abstract]   [Full Text] [Related]  

  • 31. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D; Ronchese F; Zanovello P; Biasi G; Chieco-Bianchi L
    J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
    [No Abstract]   [Full Text] [Related]  

  • 32. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
    Wood GW
    Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The lymphocyte response to primary Moloney sarcoma virus tumors: definition of a non-specific component of the in vitro cellular hyporeactivity of tumor-bearing hosts.
    Kiessling R; Bataillon G; Lamon EW; Klein E
    Int J Cancer; 1974 Nov; 14(5):642-8. PubMed ID: 4459279
    [No Abstract]   [Full Text] [Related]  

  • 34. Synergistic or antgonistic effect of different antibody concentrations on in vitro lymphocyte cytotoxicity in the Moloney sarcoma virus system.
    Skurzak HM; Klein E; Yoshida TO; Lamon EW
    J Exp Med; 1972 Apr; 135(4):997-1002. PubMed ID: 5018057
    [No Abstract]   [Full Text] [Related]  

  • 35. Cell-surface and virion-envelope antigens shared by radiation leukemia virus (RadLV) and other murine c-type viruses.
    Ferrer JF
    Int J Cancer; 1973 Sep; 12(2):378-88. PubMed ID: 4134124
    [No Abstract]   [Full Text] [Related]  

  • 36. The cellular events associated with regression and progression of murine (Moloney) sarcomas.
    Russell SW; Cochrane CG
    Int J Cancer; 1974 Jan; 13(1):54-63. PubMed ID: 4856384
    [No Abstract]   [Full Text] [Related]  

  • 37. Serological analysis of cell surface antigens of tumors induced by murine leukemia virus.
    Herberman RB
    J Natl Cancer Inst; 1972 Jan; 48(1):265-71. PubMed ID: 4119883
    [No Abstract]   [Full Text] [Related]  

  • 38. Secondary in vitro generation of cytolytic T-lymphocytes (CTL's) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier.
    Collavo D; Parenti A; Biasi G; Chieco-Bianchi L; Colombatti A
    J Natl Cancer Inst; 1978 Sep; 61(3):885-90. PubMed ID: 80457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-mediated immunity to Moloney sarcoma virus in mice. II. Analysis of antigenic specificities involved in T lymphocyte-mediated in vivo rejection of murine sarcoma virus-induced tumors.
    Gorczynski RM; Knight RA
    Eur J Immunol; 1975 Feb; 5(2):148-55. PubMed ID: 1086221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo growth and antigenic properties of a rat sarcoma induced by Moloney sarcoma virus.
    Jones JM; Jensen F; Veit B; Feldman JD
    J Natl Cancer Inst; 1974 Jun; 52(6):1771-7. PubMed ID: 4134500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.